Our dual agonist peptide therapy targets both the GLP-1 and GIP receptors—two key hormones involved in regulating blood sugar, insulin response, and appetite. By activating these pathways, this compound promotes significant weight loss

Its dual-receptor mechanism sets it apart from traditional GLP-1 agonists, offering a more comprehensive approach to managing insulin resistance and overeating.

Sourced from licensed U.S. compounding pharmacies operating under FDA and cGMP guidelines, this therapy meets the highest standards of safety, potency, and consistency.

Contact us to learn more